标题
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
作者
关键词
-
出版物
Biomedicines
Volume 9, Issue 9, Pages 1075
出版商
MDPI AG
发表日期
2021-08-25
DOI
10.3390/biomedicines9091075
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
- (2021) Rangarirai Makuku et al. Journal of Immunology Research
- The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy
- (2021) Zahra Asadzadeh et al. BIOMEDICINE & PHARMACOTHERAPY
- From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy
- (2021) Afshin Derakhshani et al. MOLECULES
- The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead
- (2021) Negar Hosseinkhani et al. Frontiers in Immunology
- Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine
- (2021) Afshin Derakhshani et al. Cancers
- Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs
- (2021) Afshin Derakhshani et al. Journal of Personalized Medicine
- Quorum Regulation via Nested Antagonistic Feedback Circuits Mediated by the Receptors CD28 and CTLA-4 Confers Robustness to T Cell Population Dynamics
- (2020) Simon Zenke et al. IMMUNITY
- Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis
- (2020) David Schafflick et al. Nature Communications
- Transcriptomic Profiling of Tumor-Infiltrating CD4+TIM-3+ T Cells Reveals Their Suppressive, Exhausted, and Metastatic Characteristics in Colorectal Cancer Patients
- (2020) Varun Sasidharan Nair et al. Vaccines
- Exosome-encapsulated miRNAs contribute to CXCL12/CXCR4-induced liver metastasis of colorectal cancer by enhancing M2 polarization of macrophages
- (2020) Dong Wang et al. CANCER LETTERS
- A phase II study of anti-PD1 monoclonal antibody (Nivolumab) administered in combination with anti-LAG3 monoclonal antibody (Relatlimab) in patients with metastatic melanoma naive to prior immunotherapy in the metastatic setting.
- (2020) Anjali Rohatgi et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC).
- (2020) Dustin A. Deming et al. JOURNAL OF CLINICAL ONCOLOGY
- ST2 and regulatory T cells in the colorectal adenoma/carcinoma microenvironment: implications for diseases progression and prognosis
- (2020) Guanglin Cui et al. Scientific Reports
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer
- (2020) Eric X. Chen et al. JAMA Oncology
- Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death
- (2020) Zahra Asadzadeh et al. Cancers
- FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer
- (2020) Yue Guan et al. Frontiers in Oncology
- AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
- (2020) Carlotta Antoniotti et al. BMC CANCER
- Multicenter phase 1/2 Trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP Trial)
- (2020) Akihito Kawazoe et al. CLINICAL CANCER RESEARCH
- The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
- (2020) Omid Kooshkaki et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
- (2020) Omid Kooshkaki et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Toxicity in combination immune checkpoint inhibitor and radiation therapy: a systematic review and meta-analysis
- (2020) Congzhou M. Sha et al. RADIOTHERAPY AND ONCOLOGY
- Tim-3 finds its place in the cancer immunotherapy landscape
- (2020) Nandini Acharya et al. Journal for ImmunoTherapy of Cancer
- Overcoming Tumor Resistance to Oncolyticvaccinia Virus with Anti-PD-1-Based Combination Therapy by Inducing Antitumor Immunity in the Tumor Microenvironment
- (2020) So Young Yoo et al. Vaccines
- Varied functions of immune checkpoints during cancer metastasis
- (2020) Ali Safarzadeh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune checkpoints in tumor microenvironment and their relevance to the development of cancer stem cells
- (2020) Neda Khosravi et al. LIFE SCIENCES
- MicroRNAs and lncRNAs—A New Layer of Myeloid-Derived Suppressor Cells Regulation
- (2020) Elham Safarzadeh et al. Frontiers in Immunology
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- MiR-873/PD-L1 axis regulates the stemness of breast cancer cells
- (2019) Lanlan Gao et al. EBioMedicine
- Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
- (2019) Geoffrey T. Gibney et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy in colorectal cancer: rationale, challenges and potential
- (2019) Karuna Ganesh et al. Nature Reviews Gastroenterology & Hepatology
- Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors.
- (2019) Neil Howard Segal et al. JOURNAL OF CLINICAL ONCOLOGY
- Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation
- (2019) Takeo K. Maeda et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: implications for combination therapies
- (2019) Yijun Jia et al. INTERNATIONAL JOURNAL OF CANCER
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer
- (2019) Jakob Nikolas Kather et al. BRITISH JOURNAL OF CANCER
- Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
- (2019) Nataliya Volodymyrivna Uboha et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of Nivolumab plus Low‐Dose Ipilimumab in Previously Treated Microsatellite Instability‐High/Mismatch Repair‐Deficient Metastatic Colorectal Cancer
- (2019) Michael A. Morse et al. ONCOLOGIST
- LAG-3 antagonists by cancer treatment: a patent review
- (2019) Martin Perez-Santos et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Combination of CTLA-4 and PD-1 blockers for treatment of cancer
- (2019) Anand Rotte JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy
- (2019) Xiaojie Yu et al. mAbs
- CD4+ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B
- (2019) Yuejiao Dong et al. BMC IMMUNOLOGY
- Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
- (2019) Alessandro Leonetti et al. DRUG RESISTANCE UPDATES
- Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth
- (2019) Yuanyuan Sun et al. Immunotherapy
- Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy
- (2019) Michael A. Morse et al. ONCOLOGIST
- Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer
- (2019) E Fiegle et al. NEOPLASIA
- LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer
- (2019) Cinzia Solinas et al. Cancers
- Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies
- (2019) Philippe Armand et al. BLOOD
- Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab
- (2019) Alexandre A. Jácome et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Promising approaches in cancer immunotherapy
- (2019) Nima Taefehshokr et al. IMMUNOBIOLOGY
- Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma
- (2019) Ian T. Logan et al. JOURNAL OF IMMUNOTHERAPY
- Colorectal cancer
- (2019) Evelien Dekker et al. LANCET
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
- (2019) Shuang Qin et al. Molecular Cancer
- Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer
- (2019) Yang Xiong et al. Nanomedicine-Nanotechnology Biology and Medicine
- Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma
- (2019) Tobias A. W. Holderried et al. Clinical Epigenetics
- A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
- (2019) Mark Yarchoan et al. Cancer Medicine
- T Cell Dysfunction in Cancer
- (2018) Daniela S. Thommen et al. CANCER CELL
- Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma
- (2018) Zachary J. Brown et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment
- (2018) Ganjun Yu et al. Cellular & Molecular Immunology
- Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
- (2018) Yinghao Zhao et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Results and challenges of immune checkpoint inhibitors in colorectal cancer
- (2018) Sheik Emambux et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene
- (2018) Kristin Nicole Berger et al. GENE
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Safety of combining radiotherapy with immune-checkpoint inhibition
- (2018) William L. Hwang et al. Nature Reviews Clinical Oncology
- Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
- (2018) Alberto Carretero-González et al. Oncotarget
- Immunotherapy of Colon Cancer
- (2018) Alexander Stein et al. Oncology Research and Treatment
- PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
- (2018) Magalie Dosset et al. OncoImmunology
- Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer
- (2018) Guoying Zhou et al. OncoImmunology
- Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
- (2018) Lillian Sun et al. Journal for ImmunoTherapy of Cancer
- Revealing the atomistic details behind the binding of B7–1 to CD28 and CTLA-4: A comprehensive protein-protein modelling study
- (2018) Aravindhan Ganesan et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
- (2018) Lee-Shing Chang et al. ENDOCRINE REVIEWS
- Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials
- (2018) Bo Zhang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Cancer-associated fibroblasts: Secretions, interactions, and therapy
- (2018) Bagher Farhood et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
- (2018) David S. Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer
- (2018) Yuan Li et al. Nanoscale
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
- (2018) Anastasia Constantinidou et al. PHARMACOLOGY & THERAPEUTICS
- Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
- (2018) Yiyi Yan et al. Frontiers in Immunology
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Immune-related adverse events of immune checkpoint inhibitors: a brief review
- (2018) G. Myers Current Oncology
- Current status of immunotherapy in metastatic colorectal cancer
- (2018) Pawel Wrobel et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Cancer immunoediting and resistance to T cell-based immunotherapy
- (2018) Jake S. O’Donnell et al. Nature Reviews Clinical Oncology
- Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters
- (2018) Heinz Schmidberger et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Clinicopathological analysis of PD-L2 expression in colorectal cancer
- (2018) Peng-da Guo et al. OncoTargets and Therapy
- TIM-3, a promising target for cancer immunotherapy
- (2018) Yayi He et al. OncoTargets and Therapy
- Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
- (2018) Lukasz Kuryk et al. OncoImmunology
- PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
- (2018) Neda Yaghoubi et al. BIOMEDICINE & PHARMACOTHERAPY
- Recent developments in small molecule therapies for renal cell carcinoma
- (2017) Minsoo Song EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- EGFR TKI combination with immunotherapy in non-small cell lung cancer
- (2017) Myung-Ju Ahn et al. Expert Opinion On Drug Safety
- The colorectal cancer immune microenvironment and approach to immunotherapies
- (2017) Minoru Koi et al. Future Oncology
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients
- (2017) Yang Zhang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Cancer Therapy Due to Apoptosis: Galectin-9
- (2017) Koji Fujita et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immune Checkpoints as a Target for Colorectal Cancer Treatment
- (2017) Alessandro Passardi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).
- (2017) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors
- (2017) Laetitia Marisa et al. JNCI-Journal of the National Cancer Institute
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
- (2017) Christopher R Heery et al. LANCET ONCOLOGY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
- (2017) Bert H. O’Neil et al. PLoS One
- Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
- (2017) Claire Lhuillier et al. SEMINARS IN CANCER BIOLOGY
- PD-1 checkpoint inhibition: Toxicities and management
- (2017) Andrew W. Hahn et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- PD1 signal transduction pathways in T cells
- (2017) Hugo Arasanz et al. Oncotarget
- Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
- (2017) Shuguang Tan et al. Protein & Cell
- The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors
- (2017) Laetitia Marisa et al. JNCI-Journal of the National Cancer Institute
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo
- (2017) Lei Yin et al. Therapeutics and Clinical Risk Management
- PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation
- (2017) Huanbin Wang et al. OncoImmunology
- Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy
- (2017) Catherine A. Sabatos-Peyton et al. OncoImmunology
- CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
- (2017) Nan Chen et al. OncoImmunology
- Radiotherapy combination opportunities leveraging immunity for the next oncology practice
- (2016) Fernanda G. Herrera et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
- (2016) Xiaohong Wang et al. CANCER RESEARCH
- Lymphocyte-activation gene-3, an important immune checkpoint in cancer
- (2016) Yayi He et al. CANCER SCIENCE
- Reversing T-cell Dysfunction and Exhaustion in Cancer
- (2016) H. M. Zarour CLINICAL CANCER RESEARCH
- Ipilimumab and Bevacizumab in Glioblastoma
- (2016) T. Carter et al. CLINICAL ONCOLOGY
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
- (2016) Karishma Rajani et al. MOLECULAR THERAPY
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors
- (2016) Ameet K. Mishra et al. Oncotarget
- PD-1 and its ligands are important immune checkpoints in cancer
- (2016) Yinan Dong et al. Oncotarget
- Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis
- (2016) Madison Black et al. Oncotarget
- The concept of immune surveillance against tumors: The first theories
- (2016) Domenico Ribatti Oncotarget
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- (2016) Claire F. Friedman et al. JAMA Oncology
- PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
- (2015) F. Massari et al. CANCER TREATMENT REVIEWS
- Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity
- (2015) Alison M. Paterson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
- (2015) Giovanna Scapin et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Confusing signals: Recent progress in CTLA-4 biology
- (2015) Lucy S.K. Walker et al. TRENDS IN IMMUNOLOGY
- The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy
- (2015) Yanping Xiao et al. Cancer Discovery
- Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
- (2015) Giovanna Scapin et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer
- (2015) Benling Xu et al. Oncotarget
- Tim-3 and Tim-4 as the potential targets for antitumor therapy
- (2015) Lin Cheng et al. Human Vaccines & Immunotherapeutics
- Pharmacologic resistance in colorectal cancer: a review
- (2015) William A. Hammond et al. Therapeutic Advances in Medical Oncology
- TIMgenes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity
- (2015) Gordon J. Freeman et al. IMMUNOLOGICAL REVIEWS
- PD-1+ CD8+ T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients
- (2014) X Wu et al. BRITISH JOURNAL OF CANCER
- Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells
- (2014) D. Alizadeh et al. CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Immune Checkpoint Blockade
- (2014) Jarushka Naidoo et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Regulation of T cell responses by the receptor molecule Tim-3
- (2014) Jacob V. Gorman et al. IMMUNOLOGIC RESEARCH
- The Common -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
- (2014) A. L. Kinter et al. JOURNAL OF IMMUNOLOGY
- Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II
- (2014) Bitao Liang et al. JOURNAL OF IMMUNOLOGY
- NK cells and T cells cooperate during the clinical course of colorectal cancer
- (2014) Giuseppe Sconocchia et al. OncoImmunology
- Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
- (2014) Antonio M Grimaldi et al. OncoImmunology
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
- (2013) Maria Jure-Kunkel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
- (2013) Barbara Merelli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The Gastrointestinal Tumor Microenvironment
- (2013) Michael Quante et al. GASTROENTEROLOGY
- Myeloid-derived suppressor cells in cancer: recent progress and prospects
- (2013) Yazan S Khaled et al. IMMUNOLOGY AND CELL BIOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients with Colorectal Carcinoma
- (2013) Bin Zhang et al. PLoS One
- Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
- (2013) Liza B John et al. OncoImmunology
- Immunotherapy of cancer in 2012
- (2012) John M. Kirkwood et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
- (2012) Alexandre Calon et al. CANCER CELL
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts
- (2012) L J A C Hawinkels et al. ONCOGENE
- Hallmarks of cancer: Interactions with the tumor stroma
- (2010) Kristian Pietras et al. EXPERIMENTAL CELL RESEARCH
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
- (2010) Ki Y. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- The Perioperative Period is an Underutilized Window of Therapeutic Opportunity in Patients With Colorectal Cancer
- (2009) Gerben J. van der Bij et al. ANNALS OF SURGERY
- Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
- (2009) B. Li et al. CLINICAL CANCER RESEARCH
- The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression
- (2009) Dingcheng Gao et al. TRENDS IN MOLECULAR MEDICINE
- Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody
- (2008) Luis H Camacho EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Structural Features of Galectin-9 and Galectin-1 That Determine Distinct T Cell Death Pathways
- (2008) Shuguang Bi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer
- (2008) Paul Salama et al. JOURNAL OF CLINICAL ONCOLOGY
- The tumor microenvironment and its role in promoting tumor growth
- (2008) T L Whiteside ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now